Abstract: Embodiments of the invention generally provide compositions of crystalline zeolite materials with tailored crystal habits and the methods for forming such crystalline zeolite materials. The methods for forming the crystalline zeolite materials include binding one or more zeolite growth modifiers (ZGMs) to the surface of a zeolite crystal, which results in the modification of crystal growth rates along different crystallographic directions, leading to the formation of zeolites having a tailored crystal habit. The improved properties enabled by the tailored crystal habit include a minimized crystal thickness, a shortened internal diffusion pathlength, and a greater step density as compared to a zeolite having the native crystal habit prepared by traditional processes. The tailored crystal habit provides the crystalline zeolite materials with an aspect ratio of about 4 or greater and crystal surfaces having a step density of about 25 steps/?m2 or greater.

Abstract: In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.

Abstract: In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium oxalate crystal growth. In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium phosphate crystal growth. In some embodiments, such a composition comprises at least one citrate derivative of an organic acid and at least one pharmaceutically acceptable carrier. In another embodiment, the present disclosure relates to a method of controlling calcium oxalate crystal growth in a subject in need thereof. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease.

Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.

Abstract: Methods of controlling crystal polymorphism in organic-free synthesis of Na-Zeolites and the zeolite crystals formed using those methods are provided. The methods disclosed herein create certain types of zeolite crystals more efficiently than other previously known methods. The methods also create certain types of zeolite crystals in a form and concentration not previously disclosed. The methods disclosed herein generally comprise using solutions with varying ratios of silicon (Si), aluminum (Al), hydroxide (OH), and water. Some implementations of the invention disclosed include efficient methods of producing nearly pure cancrinite (CAN), methods of obtaining sodalite in solutions with a high Si/Al ratio, and a method of forming thin, platelet-like ANA crystals with a width of less than about 1 ?m and a length of at least about 3 ?m.

Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. R1a—O-(-A-L-)m-A-O—R1b??I, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

Abstract: Embodiments of the invention generally provide compositions of crystalline zeolite materials with tailored crystal habits and the methods for forming such crystalline zeolite materials. The methods for forming the crystalline zeolite materials include binding one or more zeolite growth modifiers (ZGMs) to the surface of a zeolite crystal, which results in the modification of crystal growth rates along different crystallographic directions, leading to the formation of zeolites having a tailored crystal habit. The improved properties enabled by the tailored crystal habit include a minimized crystal thickness, a shortened internal diffusion pathlength, and a greater step density as compared to a zeolite having the native crystal habit prepared by traditional processes. The tailored crystal habit provides the crystalline zeolite materials with an aspect ratio of about 4 or greater and crystal surfaces having a step density of about 25 steps/?m2 or greater.

Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. R1a—O-(-A-L-)m-A-O—R1b??I, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.